India leads the ways with the highest number of approved biosimilars.
The PIP code pharmacy procurement system now covers hospital-only drugs.
Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital-only drugs. The PIP code, a unique seven-digit coding system used to ensure traceability and accurate product information when ordering pharmaceutical products, was previously used only for products available in the community pharmacy setting.
In 2018, C+D began working with the UK’s National Health Service by supplying accurate medicinal data based on the PIP code system, with the latest expansion to hospital-only drugs part of an effort to better serve secondary care pharmacies and logistics teams, especially for hospital-only lines such as cytotoxics and injectables.
“Since 1982, C+D have co-owned the licensing rights to the PIP code,” C+D told Generics Bulletin. “This means we have helped get primary care products into a unique, central database that can be used for accurate ordering, dispensing and tracking of drugs across the UK.”
“C+D helps generics firms receive unique codes for their products, meaning that generic products can more easily be ordered, dispensed and tracked,” C+D said. “A primary or secondary care pharmacist will always prefer using PIP codes as it aids drug administration and patient safety.”
Emphasizing that the system comprehensively validates drug information, C+D noted that when generics firms use PIP codes “it also puts their products on competitive landscape views in our intelligence service, as we take all listed products and push them into analytics dashboards which help people make better purchasing decisions.” This, the organization maintains, boosts sales and allows products to be easily read and processed by wholesalers and distributors.
“We encourage all manufacturers supplying the NHS with POM, P, GSL or devices to reach us on email@example.com so we can input your data onto our database,” C+D insisted, referring to the UK categorizations for prescription-only medicines, drugs dispensed in a pharmacy without prescription but under the supervision of a pharmacist, and products on the general sale list.
“By not listing with C+D, generics firms are restricting the fuller sale of their products and making the traceability of their product from manufacturing site to pharmacy more difficult and increasingly likely for errors along the way. This costs UK pharmacy time, money and lives.”
In Vivo: strategic insights for life sciences decision-maker...
The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: